SCHEMBL279942

SCHEMBL279942

Cc1nnc(SCC(=O)c2ccc(C)s2)o1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 5/20 0.49
NPC1 O15118 4/20 0.47
RAB9A P51151 4/20 0.47
PKM P14618 2/20 0.46
ALDH1A1 P00352 5/20 0.44
NPSR1 Q6W5P4 2/20 0.44
GAA P10253 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
MAPT P10636 7/20 0.43
HPGD P15428 3/20 0.43
HTT P42858 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MAPK1 P28482 1/20 0.41
POLB P06746 2/20 0.41
RECQL P46063 2/20 0.41
BLM P54132 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
TSHR P16473 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22607229 0.75 MAPT (0.64) HSD17B10NPC1RAB9AALDH1A1MEN1
SCHEMBL11522171 0.74 HSD17B10 (0.53) HSD17B10PKMALDH1A1NPSR1GAA
SCHEMBL13060968 0.72 RAB9A (0.50) HSD17B10NPC1RAB9APKMALDH1A1
SCHEMBL22607228 0.71 MAPT (0.61) HSD17B10ALDH1A1NPSR1GAAMAPT
SCHEMBL11522174 0.71 PKM (0.59) HSD17B10NPC1RAB9APKMGAA
SCHEMBL279739 0.69 ALDH1A1 (0.47) HSD17B10NPC1RAB9APKMALDH1A1
SCHEMBL15979700 0.68 DAO (0.61) NPC1RAB9AALDH1A1MEN1KMT2A
SCHEMBL280052 0.67 MAPT (0.41) HSD17B10NPC1RAB9AALDH1A1NPSR1
SCHEMBL9372669 0.66 DAO (0.59) NPC1RAB9AALDH1A1MEN1KMT2A
SCHEMBL4140001 0.66 DAO (0.59) NPC1RAB9AALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL HSD17B10 4112/4885NPC1 3107/4885RAB9A 2458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.